Abstract | Keywords | Free access | Buy the book | Export citation |

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

FTO licensing in the pharmaceutical industry deserves special consideration because of the large economic scale of the market, expensive cost of R&D, extremely low success rate, and easy duplication of the drug. Taking these unique aspects into consideration, the author first explaines how to perform a good FTO search and conclude an appropriate FTO licensing agreement, and then points out two issues; (i) the issue of FTO licensing and EU competition, especially the unreasonable application of the Guideline, and (ii) the issue of FTO licensing and differentiating between a bio venture company and a pharmaceutical company. Solutions for these issues are proposed.

Patent, EU competition law, FTO, FTO-licensing market, Freedom to Operate, pharmaceutical industry, License, antitrust law, Pharmaceutical